Is it past time for a new approach to the COVID vaccine? Ocugen Chairman of the Board, Founder, & CEO Shankar Musunuri, Ph.D., says yes, and his ideals would mark significant improvements: fewer shots, better durability, less post-vaccination transmission, and safety proven by time-tested technology. How would such a vaccine be produced? Musunuri lays out the manufacturing science on this week's episode of the Business of Biotech. Listen now!
Should business leaders speak out on the social and political issues that intermingle with the buying and selling of goods and services? Opinions vary … widely.
Tasked with driving future growth of Takeda’s plasma-derived therapies, Giles Platford, business unit president, shares his approach to partnering, promoting market access, and improving patient experiences.
When it comes to outsourced clinical manufacturing, respondents allocate the largest proportion of project volume to a combination of drug substance and drug product CDMOs.
For yet another year, COVID-19 and pandemic-related factors shaped the biopharmaceutical industry. It stretched supply chains and claimed qualified staff who otherwise would have been developing other drugs. BioPlan Associates, which publishes an annual industry survey, looks back on the biggest trends of 2022.
While the first autologous cell therapy commercial products have shown tremendous clinical success, scaling out these therapies while considering individual patient processes is a new challenge.
Addressing data management challenges during drug development requires an understanding of today’s shortcomings and the factors to consider when adopting a solution to overcome them.
Discover key upstream and downstream considerations for process development for RNA drug substance manufacturing and the parameters that need construct-specific optimization to increase yield and reduce impurities.
Through two online surveys, one focused on the Phase 1 space and another focused on the Phase 2/3 space, recent customers have evaluated the performance of 50 CROs across 20+ attributes.
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
Connect With Life Science Leader:
This website uses cookies to ensure you get the best experience on our website. Learn more
